OmniComm Systems (Ft. Lauderdale, FL) announced that it has been selected by an unnamed biopharmaceutical company to provide eClinical solutions for two of its Phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for seven months. The company has already used OmniComm Systems in different therapeutic areas.

OmniComm recently announced acquisitions of EDC assets of ERT and Logos Technologies. 

OmniComm Systems To Provide eClinical Solutions for two Phase I HIV Studies